Prostate‐specific antigen (PSA) complexed to α1‐antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0–4.0 ng/mL
Prostate‐specific antigen (PSA) complexed to α1‐antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0–4.0 ng/mL
复制标题
前列腺特异性抗原 (PSA) 与 α1-抗胰凝乳蛋白酶复合，使用总 PSA 改善总 PSA 水平为 2.0–4.0 ng/mL 的日本患者的前列腺癌检测
作者：
Takashi Kobayashi;T. Kamoto;K. Nishizawa;K. Mitsumori;K. Ogura;Yoshi
在总PSA水平为2.0-4.0 ng/mL的日本男性中，评估前列腺特异性抗原（PSA）与α1-抗糜蛋白酶（PSA-ACT）复合物在前列腺癌筛查中的效用，因为提高总PSA水平为2.0-4.0 ng/mL的男性的癌症检出率对临床泌尿科医生来说是一项挑战。
To assess the utility of prostate‐specific antigen (PSA) complexed to α1‐antichymotrypsin (PSA‐ACT) in prostate cancer screening in Japanese men with a total PSA level of 2.0–4.0 ng/mL, as improving cancer detection in men with these total PSA levels is a challenge for clinical urologists.